{"id":82588,"date":"2020-04-16T13:40:44","date_gmt":"2020-04-16T17:40:44","guid":{"rendered":"https:\/\/linitiative.ca\/International\/article-1060668\/"},"modified":"2020-04-16T13:40:44","modified_gmt":"2020-04-16T17:40:44","slug":"article-1060668","status":"publish","type":"post","link":"https:\/\/linitiative.ca\/International\/article-1060668\/","title":{"rendered":"Article 1060668"},"content":{"rendered":"<div class=\"body\">\n<div class=\"field field-name-body field-type-text-with-summary field-label-hidden\">\n<div class=\"field-items\" readability=\"8.5\">\n<div class=\"field-item even\" property=\"content:encoded\" readability=\"12\">\n<p class=\"rtejustify\">Le M\u00e9thotrexate, m\u00e9dicament pr\u00e9conis\u00e9 dans le traitement du cancer et en rhumatologie dans le traitement de la polyarthrite rhumato\u00efde et du lupus \u00e9ryth\u00e9mateux est de nouveau indisponible en officine comme chez les distributeurs ou en laboratoires, depuis plus d\u2019un mois. Aucune indication n\u2019est donn\u00e9e sur les mesures entreprises pour alimenter les stocks.\u00a0 Les malades chroniques en rhumatologie et patients trait\u00e9s \u00e0 base de ces m\u00e9dicaments seront-ils les victimes collat\u00e9rales du Covid-19?<\/p>\n<p class=\"rtejustify\"><em>A.K. <\/em><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"eco-conseil\">\n<div class=\"view view-eco-conseil-16 view-id-eco_conseil_16 view-display-id-cookies view-dom-id-49fca48fee16b8e67ba35ab5862cb57c\">\n<div class=\"view-content\">\n<div id=\"views-bootstrap-grid-1\" class=\"views-bootstrap-grid-plugin-style\">\n<div class=\"row\">\n<div class=\" col-xs-12 col-lg-4\">\n<div class=\"row\">\n<div class=\"col col-xs-12 col-lg-12\">\n<div class=\"field-content\"><a href=\"\/article\/1060667-ram-plein-de-sources-de-vulnerabilites-denoncees\"><img loading=\"lazy\" decoding=\"async\" class=\"img-responsive\" typeof=\"foaf:Image\" src=\"https:\/\/www.leconomiste.com\/sites\/default\/files\/eco7\/public\/styles\/800x400\/public\/default_images\/default_une.jpg?itok=4jZlgnIZ\" width=\"660\" height=\"330\" alt=\"\"\/><\/a><\/div>\n<\/div>\n<div class=\" title_suite_2 col col-xs-12 col-lg-12\"> <a href=\"\/article\/1060667-ram-plein-de-sources-de-vulnerabilites-denoncees\"\/><span class=\"field-content\"> RAM: Plein de sources de vuln\u00e9rabilit\u00e9s d\u00e9nonc\u00e9es!<\/span><\/div>\n<\/div>\n<\/div>\n<div class=\" col-xs-12 col-lg-4\">\n<div class=\"row\">\n<div class=\"col col-xs-12 col-lg-12\">\n<div class=\"field-content\"><a href=\"\/article\/1060666-ram-l-umt-tire-boulets-rouges\"><img loading=\"lazy\" decoding=\"async\" class=\"img-responsive\" typeof=\"foaf:Image\" src=\"https:\/\/www.leconomiste.com\/sites\/default\/files\/eco7\/public\/styles\/800x400\/public\/default_images\/default_une.jpg?itok=4jZlgnIZ\" width=\"660\" height=\"330\" alt=\"\"\/><\/a><\/div>\n<\/div>\n<div class=\" title_suite_2 col col-xs-12 col-lg-12\"> <a href=\"\/article\/1060666-ram-l-umt-tire-boulets-rouges\"\/><span class=\"field-content\">RAM: L\u2019UMT tire \u00e0 boulets rouges<\/span><\/div>\n<\/div>\n<\/div>\n<div class=\" col-xs-12 col-lg-4\">\n<div class=\"row\">\n<div class=\"col col-xs-12 col-lg-12\">\n<div class=\"field-content\"><a href=\"\/article\/1060665-droit-l-information-le-debat-se-poursuit-avec-le-hcp\"><img loading=\"lazy\" decoding=\"async\" class=\"img-responsive\" typeof=\"foaf:Image\" src=\"https:\/\/www.leconomiste.com\/sites\/default\/files\/eco7\/public\/styles\/800x400\/public\/default_images\/default_une.jpg?itok=4jZlgnIZ\" width=\"660\" height=\"330\" alt=\"\"\/><\/a><\/div>\n<\/div>\n<div class=\" title_suite_2 col col-xs-12 col-lg-12\"> <a href=\"\/article\/1060665-droit-l-information-le-debat-se-poursuit-avec-le-hcp\"\/><span class=\"field-content\">Droit \u00e0 l\u2019information: Le d\u00e9bat se poursuit avec le HCP<\/span><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<p>Auteur: hlafriqi<br \/>\n<a href=\"https:\/\/www.leconomiste.com\/article\/1060668-le-methotrexate-de-nouveau-indisponible\">Cliquez ici pour lire l&rsquo;article depuis sa source.<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Le M\u00e9thotrexate, m\u00e9dicament pr\u00e9conis\u00e9 dans le traitement du cancer et en rhumatologie dans le traitement de la polyarthrite rhumato\u00efde et du lupus \u00e9ryth\u00e9mateux est de nouveau indisponible en officine comme chez les distributeurs ou en laboratoires, depuis plus d\u2019un mois. Aucune indication n\u2019est donn\u00e9e sur les mesures entreprises pour alimenter les stocks.\u00a0 Les malades chroniques [&hellip;]<\/p>\n","protected":false},"author":1763,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"fifu_image_url":"","fifu_image_alt":"","footnotes":""},"categories":[78,54],"tags":[],"class_list":["post-82588","post","type-post","status-publish","format-standard","hentry","category-economie","category-maroc"],"_links":{"self":[{"href":"https:\/\/linitiative.ca\/International\/wp-json\/wp\/v2\/posts\/82588","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/linitiative.ca\/International\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/linitiative.ca\/International\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/linitiative.ca\/International\/wp-json\/wp\/v2\/users\/1763"}],"replies":[{"embeddable":true,"href":"https:\/\/linitiative.ca\/International\/wp-json\/wp\/v2\/comments?post=82588"}],"version-history":[{"count":0,"href":"https:\/\/linitiative.ca\/International\/wp-json\/wp\/v2\/posts\/82588\/revisions"}],"wp:attachment":[{"href":"https:\/\/linitiative.ca\/International\/wp-json\/wp\/v2\/media?parent=82588"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/linitiative.ca\/International\/wp-json\/wp\/v2\/categories?post=82588"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/linitiative.ca\/International\/wp-json\/wp\/v2\/tags?post=82588"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}